No coverage on this generic giant? Well, that ain't right. Since every person who responds from now on will be subjected to this first post, how about a quick introduction: Ivax is a holding company comprised of several smaller drug companies. They make genric drugs, intravenous solutions, and proprietory drugs. They have more FDA approvals than any other generic drug company. Merril Lynch has recently placed Ivax on its focus recommended list calling Ivax an "uncommon value". Last Quarter, Ivax reported .30 / share which beat First Call estimates of .28/share. The stock trades in the 25-30 range and has a P/E ratio of 25.
Ivax has been the subject of Takeover talks as many "big name" drug companies realize the important role Generic drugs will play in the near future. Starting in 1998, many patents will expire and Ivax is set to capitalize on those situations. Unlike Mylan, Ivax has efficent R&D which produces money making generics, including cheaper versions of drugs made by Glaxo Welcome and Bristol Meyers Squib. Because of their stellar track record, Ivax has continually received quick FDA approval, including 18 in 1995.. This is may be a tortoise type investment, but if your'e a long term investor, it can't be beat.....Comments, questions? |
